Events/N
Median (months)
Subgroup
Eribulin
Cape
HR (95% CI)
Eribulin Cape
Overall
446/554 459/548
0.879
(0.770, 1.003)
15.9
14.5
HER2 status
Positive
73/86
73/83
0.965
(0.688, 1.355)
14.3
17.1
Negative
296/375 316/380
0.838
(0.715, 0.983)
15.9
13.5
Unknown
77/93
70/85
0.988
(0.710, 1.375)
18.7
17.2
Study 301: Overall Survival by HER2 Status
0.2
0.5
1
2
5
ITT Population.
19/83 (23%) of HER2+ capecitabine patients did not receive anti-HER2 therapy prior to study, but did receive it afterwards.
The corresponding figure for eribulin is 7/86 (8%).
